Incyte Corp (INCY) Stock Price & Analysis

Incyte Corp (INCY) rose 0.84% to USD 117.67 as of July 25, 2026 at 01:54 UTC, according to Nexqual real-time market data.

INCY last closed at USD 116.69; the session ranged USD 116.7–119.13 on volume of 1,178,006 shares. Market capitalization is $23.51B, with a 52-week range of USD 69.69–119.6 (NMS). Source: Nexqual, July 25, 2026 at 01:54 UTC.

Key Statistics (as of July 25, 2026 at 01:54 UTC)

Technical Analysis (INCY)

Nexqual's technical model rates INCY "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:54 UTC.

Analyst Ratings (INCY)

Wall Street analysts rate INCY "Buy" based on 22 analysts, with a mean price target of USD 114.55 (range USD 71–140), per Nexqual as of July 25, 2026 at 01:54 UTC.

Earnings (INCY)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 01:54 UTC.

Financials & Fundamentals (INCY)

Source: Nexqual, July 25, 2026 at 01:54 UTC.

Financial Health Score (INCY)

Nexqual rates Incyte Corp's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 01:54 UTC.

Ownership (INCY)

Source: Nexqual, July 25, 2026 at 01:54 UTC.

Leadership (INCY)

Incyte Corp is led by William J. Meury (age 57), CEO & Director, per Nexqual as of July 25, 2026 at 01:54 UTC.

Major Backers & Investors (INCY)

Notable institutional backers of Incyte Corp include Baker Bros. Advisors, LP, Dodge & Cox Inc., AQR Capital Management, LLC, according to Nexqual as of July 25, 2026 at 01:54 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 01:54 UTC.

From Incyte Corp's Latest SEC 10-K Filing (filed 2026-02-10)

Key Strengths & Strategy (as disclosed to the SEC)

• We submitted a Type II variation Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") and, in January 2026, we announced that the Committee for Medicinal Products for Human Use ("CHMP") issued a positive opinion for ZYNYZ in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC.
• In September 2025, the FDA approved the supplemental New Drug Application ("NDA") for OPZELURA for the short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable.
• Before marketing in the United States, any drug developed by us must undergo rigorous preclinical testing, clinical trials, and an extensive regulatory clearance process implemented by the FDA under the United States Food, Drug, and Cosmetic Act and its implementing regulations and, in the case of biologics, the Public Health Service Act.
• This focus allows us to allocate resources to our selected programs at a level that we believe is competitive with larger pharmaceutical companies.

Partnerships

• In October 2025, we announced an agreement with Enable Injections, Inc. ("Enable") to develop for use with specific assets in our portfolio, including INCA033989, Enable's enFuse on-body delivery system.
• In May 2020, we amended our agreement with Lilly to enable Lilly to commercialize baricitinib for the treatment of COVID-19.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:54 UTC. This page is informational and not investment advice.